NCT01343719View on ClinicalTrials.gov

Single Rising Dose Study to Assess Safety, Tolerability and Pharmacokinetics of BI 661051.

PHASE1CompletedINTERVENTIONAL
Enrollment

64

Participants

Timeline

Start Date

April 30, 2011

Primary Completion Date

July 31, 2011

Conditions
Healthy
Interventions
DRUG

BI 661051

medium dose solution for oral administration

DRUG

BI 661051

medium dose solution for oral administration

DRUG

BI 661051

medium dose solution for oral administration

DRUG

BI 661051

low dose solution for oral administration

DRUG

BI 661051

low dose solution for oral administration

DRUG

BI 661051

low dose solution for oral administration

DRUG

BI 661051

high dose solution for oral administration

DRUG

BI 661051

high dose solution for oral administration

DRUG

BI 661051

low dose tablet

DRUG

Placebo

solution for administration

DRUG

BI 661051

medium dose tablet

Trial Locations (1)

Unknown

1296.1.1 Boehringer Ingelheim Investigational Site, Mannheim

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY